ENZ - Enzo Biochem, Inc.

NYSE - NYSE Delayed Price. Currency in USD
2.5900
+0.0400 (+1.57%)
At close: 4:02PM EST
Stock chart is not supported by your current browser
Previous Close2.5500
Open2.5500
Bid2.5900 x 1000
Ask2.7100 x 800
Day's Range2.5450 - 2.6541
52 Week Range2.4000 - 4.4600
Volume116,276
Avg. Volume82,219
Market Cap123.172M
Beta (5Y Monthly)1.17
PE Ratio (TTM)172.67
EPS (TTM)0.0150
Earnings DateDec 09, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.50
  • Business Wire

    All Three Proxy Advisory Firms Recommend Shareholders Vote FOR Change to the Board of Enzo Biochem on the Blue Card

    Harbert Discovery Fund, LP and Harbert Discovery Co-Investment Fund I, LP (collectively "HDF"), the beneficial owners of more than 11.8% of the outstanding shares of Enzo Biochem, Inc. (NYSE: ENZ) ("Enzo" or the "Company"), today announced that Egan-Jones Proxy Services ("Egan-Jones") has recommended shareholders vote for both HDF nominees on the Blue proxy card. All three leading proxy advisors – Egan-Jones, Glass, Lewis and Co. ("Glass Lewis") and Institutional Shareholder Services Inc. ("ISS") – have now supported HDF’s case for change at Enzo.

  • Business Wire

    Enzo Biochem Comments on ISS Report

    Enzo Biochem, Inc. (NYSE:ENZ), an integrated diagnostics and life sciences company focusing on delivering and applying advanced technology capabilities to produce affordable, reliable and fully-automated platforms and related products and services that enable its customers to meet their clinical needs, today commented on the report Institutional Shareholder Services (ISS) issued in connection with the upcoming Annual Shareholder Meeting.

  • Business Wire

    ISS Recommends Shareholders Vote FOR the Election of Harbert Discovery Fund Nominee to Enzo Biochem Board

    Harbert Discovery Fund, LP and Harbert Discovery Co-Investment Fund I, LP (collectively "HDF"), the beneficial owners of more than 11.8% of the outstanding shares of Enzo Biochem, Inc. (NYSE: ENZ) ("Enzo" or the "Company"), today announced that a leading proxy advisory firm, Institutional Shareholder Services Inc. ("ISS"), has recommended that shareholders vote on the BLUE proxy card in support of HDF’s nominee, Fabian Blank.

  • Business Wire

    Glass Lewis Recommends Shareholders Vote For the Election of Both Harbert Discovery Fund Nominees to Enzo Biochem’s Board

    Harbert Discovery Fund, LP and Harbert Discovery Co-Investment Fund I, LP (collectively "HDF"), the beneficial owners of more than 11.8% of the outstanding shares of Enzo Biochem, Inc. (NYSE: ENZ) ("Enzo" or the "Company"), today announced that a leading proxy advisory firm, Glass, Lewis & Co. ("Glass Lewis"), has recommended that shareholders vote on the BLUE proxy card in support of HDF’s two highly-qualified independent nominees, Fabian Blank and Peter Clemens.

  • Business Wire

    Enzo Biochem Responds to Series of Misleading and Inaccurate Statements from Activist Hedge Fund Harbert

    The Board of Directors of Enzo Biochem, Inc. (NYSE:ENZ), an integrated diagnostics and life sciences company focusing on delivering and applying advanced technology capabilities to produce affordable, reliable and fully-automated platforms and related products and services that enable its customers to meet their clinical needs, today responded to a series of misleading and inaccurate statements in an investor presentation and press release filed by activist investor Harbert Discovery Fund ("Harbert") regarding the Company’s significant accomplishments. The Board believes that Harbert’s campaign of disinformation is designed to divert attention from its inferior slate of underqualified nominees and weak arguments bereft of any true understanding of Enzo’s business or market. With Harbert steadfastly seeking to change 40% of the Board (which would result in only a single independent director remaining with more than a few weeks of experience on our Board), it is critical that the Company set the record straight so shareholders can make a fully informed decision at the upcoming Annual Shareholder meeting.

  • Business Wire

    Harbert Discovery Fund Releases Detailed Investor Presentation Highlighting Case for Change at Enzo Biochem

    Harbert Discovery Fund, LP and Harbert Discovery Co-Investment Fund I, LP (collectively "HDF"), the beneficial owner of more than 11.8% of the outstanding shares of Enzo Biochem, Inc. (NYSE: ENZ) ("Enzo" or the "Company"), today released a detailed investor presentation on Enzo. The presentation outlines the Company’s history of value destruction, persistent underperformance, and corporate governance issues and details HDF’s Nominees’ strategic plan to realize value at Enzo.

  • How Does Enzo Biochem, Inc. (NYSE:ENZ) Affect Your Portfolio Volatility?
    Simply Wall St.

    How Does Enzo Biochem, Inc. (NYSE:ENZ) Affect Your Portfolio Volatility?

    Anyone researching Enzo Biochem, Inc. (NYSE:ENZ) might want to consider the historical volatility of the share price...

  • Business Wire

    Enzo Biochem Appoints Rebecca J. Fischer to Board of Directors

    Enzo Biochem, Inc. (NYSE:ENZ), an integrated diagnostics and life sciences company focusing on delivering and applying advanced technology capabilities to produce affordable, reliable products and services that enable its customers to meet their clinical needs, today announced it has appointed industry healthcare veteran and leader Rebecca J. Fischer to its Board of Directors. Her appointment as a new independent director is effective immediately and follows a search process conducted as part of Enzo’s ongoing focus on Board composition, refreshment and diversity. As part of our evaluation, the Company as a significant provider of Women’s health products and services, believes the representation of such a highly qualified woman on the Board would be a valuable contribution to it.

  • Business Wire

    Harbert Discovery Fund Sends Letter to Fellow Enzo Biochem Shareholders

    Harbert Discovery Fund, LP and Harbert Discovery Co-Investment Fund I, LP (collectively "HDF"), the beneficial owner of more than 11.8% of the outstanding shares of Enzo Biochem, Inc. (NYSE: ENZ) ("Enzo" or the "Company"), sent a detailed letter to shareholders today highlighting HDF’s case for change at Enzo, including the opportunity for shareholders to elect two highly-qualified, fresh voices – Fabian Blank and Peter Clemens – to the Company’s Board of Directors (the "Board") at its 2019 Annual Meeting of Shareholders, which will be held on January 31, 2020.

  • Is Enzo Biochem, Inc. (ENZ) Going To Burn These Hedge Funds ?
    Insider Monkey

    Is Enzo Biochem, Inc. (ENZ) Going To Burn These Hedge Funds ?

    Investing in small cap stocks has historically been a way to outperform the market, as small cap companies typically grow faster on average than the blue chips. That outperformance comes with a price, however, as there are occasional periods of higher volatility. The last 12 months is one of those periods, as the Russell 2000 […]

  • Business Wire

    Enzo Biochem Reports Fiscal First Quarter Results

    Enzo Biochem, Inc. (NYSE:ENZ), an integrated diagnostics and life sciences company focusing on delivering and applying advanced technology capabilities to produce affordable, reliable products and services that enable its customers to meet their clinical needs, today reported results for the fiscal first quarter ended October 31, 2019.

  • Business Wire

    Enzo Biochem Issues Open Letter to Shareholders

    Enzo Biochem, Inc. (NYSE:ENZ), an integrated diagnostics and life sciences company focusing on delivering and applying advanced technology capabilities to produce affordable, reliable products and services that enable its customers to meet their clinical needs, today issued an open letter to shareholders. Full text below:

  • Business Wire

    Enzo Biochem Schedules Teleconference to Discuss First Quarter 2020 Results Tuesday, December 10, 2019 At 4:30 PM E.T.

    Enzo Biochem, Inc. (NYSE:ENZ) will hold a conference call to discuss fiscal 2020 first quarter results on Tuesday, December 10, 2019, at 4:30 PM E.T.

  • What Kind Of Shareholders Own Enzo Biochem, Inc. (NYSE:ENZ)?
    Simply Wall St.

    What Kind Of Shareholders Own Enzo Biochem, Inc. (NYSE:ENZ)?

    Every investor in Enzo Biochem, Inc. (NYSE:ENZ) should be aware of the most powerful shareholder groups. Institutions...

  • Thomson Reuters StreetEvents

    Edited Transcript of ENZ earnings conference call or presentation 15-Oct-19 8:30pm GMT

    Q4 2019 Enzo Biochem Inc Earnings Call

  • Business Wire

    Enzo Biochem Reports Fiscal Fourth Quarter and Full Year Financial Results

    Company’s Vertically Integrated Life Sciences and Labs Business Generates Breakthrough Diagnostic Testing Approvals and Services in Rapidly Expanding Markets

  • Business Wire

    Enzo Biochem Schedules Teleconference to Discuss Fourth Quarter and Fiscal Year 2019 Results Tuesday, October 15, 2019 at 4:30 PM E.T.

    Enzo Biochem, Inc. (ENZ) will hold a conference call to discuss fiscal 2019 fourth quarter and fiscal year 2019 results on Tuesday, October 15, 2019, at 4:30 PM E.T. To listen to the conference call dial 1-888-459-5609. International callers can dial 1-973-321-1024.

  • Does Enzo Biochem, Inc.'s (NYSE:ENZ) CEO Salary Reflect Performance?
    Simply Wall St.

    Does Enzo Biochem, Inc.'s (NYSE:ENZ) CEO Salary Reflect Performance?

    Elazar Rabbani became the CEO of Enzo Biochem, Inc. (NYSE:ENZ) in 1976. This report will, first, examine the CEO...

  • Investors Who Bought Enzo Biochem (NYSE:ENZ) Shares Five Years Ago Are Now Down 41%
    Simply Wall St.

    Investors Who Bought Enzo Biochem (NYSE:ENZ) Shares Five Years Ago Are Now Down 41%

    For many, the main point of investing is to generate higher returns than the overall market. But even the best stock...

  • Is Enzo Biochem (NYSE:ENZ) Using Debt In A Risky Way?
    Simply Wall St.

    Is Enzo Biochem (NYSE:ENZ) Using Debt In A Risky Way?

    David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

  • Is Enzo Biochem, Inc.'s (NYSE:ENZ) 2.3% ROE Worse Than Average?
    Simply Wall St.

    Is Enzo Biochem, Inc.'s (NYSE:ENZ) 2.3% ROE Worse Than Average?

    One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...